Wells Fargo & Company Kazia Therapeutics LTD Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KZIA
# of Institutions
13Shares Held
328KCall Options Held
24KPut Options Held
0-
Morgan Stanley New York, NY201KShares$74,4000.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA41.5KShares$15,3460.0% of portfolio
-
Virtu Financial LLC New York, NY39.3KShares$14,5320.0% of portfolio
-
Ubs Group Ag23.3KShares$8,6340.0% of portfolio
-
Rhumbline Advisers Boston, MA17.6KShares$6,5170.0% of portfolio
About KAZIA THERAPEUTICS LTD
- Ticker KZIA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,111,300
- Market Cap $5.59M
- Description
- Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...